awmsg logo



canakinumab (Ilaris®)


Reference No. 1209

Publication date:
14/03/2017


Appraisal information

canakinumab (Ilaris®) 150 mg powder for solution for injection


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 14/03/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, canakinumab (Ilaris®) cannot be endorsed for use within NHS Wales as monotherapy or in combination with methotrexate for the treatment of active Still's disease including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids.
Statement of Advice (SOA)
Download